{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:04:45Z","timestamp":1785168285242,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Sixth People's Hospital of Shenyang"},{"name":"The National Science and Technology Major Special Project for New Drug Development"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12072-021-10235-1","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T15:02:16Z","timestamp":1627398136000},"page":"1103-1108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load"],"prefix":"10.1007","volume":"15","author":[{"given":"Baijun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaozhe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongchun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"issue":"5","key":"10235_CR1","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/AOG.0b013e3182148efe","volume":"117","author":"JS Sheffield","year":"2011","unstructured":"Sheffield JS, Hickman A, Tang J, Moss K, Kourosh A, Crawford NM, Wendel GD Jr. Efficacy of an accelerated hepatitis B vaccination program during pregnancy. Obstet Gynecol 2011;117(5):1130\u20131135","journal-title":"Obstet Gynecol"},{"key":"10235_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jcv.2016.02.003","volume":"77","author":"P Yi","year":"2016","unstructured":"Yi P, Chen R, Huang Y, Zhou RR, Fan XG. Management of mother-to-child transmission of hepatitis B virus: propositions and challenges. J Clin Virol 2016;77:32\u201339","journal-title":"J Clin Virol"},{"issue":"2","key":"10235_CR3","first-page":"85","volume":"27","author":"Y Ding","year":"2019","unstructured":"Ding Y, Sheng QJ, Dou XG. Considerations of using oral nucleos(t)ide analogues to interrupt mother-to-child transmission in HBV carrier pregnant woman with high viral load. Zhonghua Gan Zang Bing Za Zhi 2019;27(2):85\u201387 (Chinese)","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"3","key":"10235_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","volume":"97","author":"J Liu","year":"2019","unstructured":"Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease. China Bull World Health Org 2019;97(3):230\u2013238","journal-title":"China Bull World Health Org"},{"issue":"3","key":"10235_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cgh.2019.05.057","volume":"18","author":"P Sripongpun","year":"2020","unstructured":"Sripongpun P, Mannalithara A, Kwo PY, Kim WR. Potential benefits of switching liver transplant recipients to tenofovir alafenamide prophylaxis. Clin Gastroenterol Hepatol 2020;18(3):747\u2013749","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10235_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","volume":"119","author":"E De Clercq","year":"2016","unstructured":"De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol 2016;119:1\u20137","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10235_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/23744235.2017.1384957","volume":"50","author":"S Tavakolpour","year":"2018","unstructured":"Tavakolpour S, Darvishi M, Mirsafaei HS, Ghasemiadl M. Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review. Infect Dis (Lond) 2018;50(2):95\u2013106","journal-title":"Infect Dis (Lond)"},{"issue":"10","key":"10235_CR8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/jvh.13156","volume":"26","author":"J Liu","year":"2019","unstructured":"Liu J, Wang J, Yan T, Du D, Qi C, Cao F, et al. Efficacy and safety of telbivudine and tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: a real-life practice. J Viral Hepat 2019;26(10):1170\u20131177","journal-title":"J Viral Hepat"},{"key":"10235_CR9","doi-asserted-by":"publisher","first-page":"175628481878610","DOI":"10.1177\/1756284818786108","volume":"11","author":"R Byrne","year":"2018","unstructured":"Byrne R, Carey I, Agarwal K. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Therap Adv Gastroenterol 2018;11:1756284818786108","journal-title":"Therap Adv Gastroenterol"},{"issue":"06","key":"10235_CR10","first-page":"466","volume":"40","author":"WY Tian","year":"2020","unstructured":"Tian WY, Sheng QJ, Zhang C, Dou XG, Ding Y. Efficacy and safety of tenofovir alafenamide fumarate in pregnant women at HBV-infected immune-tolerant phase. Zhongguo Shiyong Neike Zazhi 2020;40(06):466\u2013470 (Chinese)","journal-title":"Zhongguo Shiyong Neike Zazhi"},{"key":"10235_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/978-94-007-5416-4_19","volume":"65","author":"DB Corlin","year":"2012","unstructured":"Corlin DB, Heegaard NH. \u03b2(2)-microglobulin amyloidosis. Subcell Biochem 2012;65:517\u2013540","journal-title":"Subcell Biochem"},{"issue":"1","key":"10235_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5527\/wjn.v4.i1.98","volume":"4","author":"A Zumrutdal","year":"2015","unstructured":"Zumrutdal A. Role of \u03b22-microglobulin in uremic patients may be greater than originally suspected. World J Nephrol 2015;4(1):98\u2013104","journal-title":"World J Nephrol"},{"key":"10235_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/8904_2015_465","volume":"25","author":"M K\u00e4rki","year":"2016","unstructured":"K\u00e4rki M, N\u00e4nt\u00f6-Salonen K, Niinikoski H, Tanner LM. Urine Beta2-Microglobulin Is an Early Marker of Renal Involvement in LPI. JIMD Rep 2016;25:47\u201355","journal-title":"JIMD Rep"},{"issue":"2","key":"10235_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ki.1984.151","volume":"26","author":"C Gauthier","year":"1984","unstructured":"Gauthier C, Nguyen-Simonnet H, Vincent C, Revillard JP, Pellet MV. Renal tubular absorption of beta 2 microglobulin. Kidney Int 1984;26(2):170\u2013175","journal-title":"Kidney Int"},{"key":"10235_CR15","doi-asserted-by":"publisher","first-page":"4647685","DOI":"10.1155\/2016\/4647685","volume":"2016","author":"T Fiseha","year":"2016","unstructured":"Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol 2016;2016:4647685","journal-title":"Int J Nephrol"},{"issue":"11","key":"10235_CR16","doi-asserted-by":"publisher","first-page":"e13262","DOI":"10.14814\/phy2.13262","volume":"5","author":"F Chacar","year":"2017","unstructured":"Chacar F, Kogika M, Sanches TR, Caragelasco D, Martorelli C, Rodrigues C, et al. Urinary Tamm-Horsfall protein, albumin, vitamin D-binding protein, and retinol-binding protein as early biomarkers of chronic kidney disease in dogs. Physiol Rep 2017;5(11):e13262","journal-title":"Physiol Rep"},{"issue":"9","key":"10235_CR17","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1097\/QAD.0000000000001466","volume":"31","author":"R Samuels","year":"2017","unstructured":"Samuels R, Bayerri CR, Sayer JA, Price DA, Payne BAI. Tenofovir disoproxil fumarate-associated renal tubular dysfunction: noninvasive assessment of mitochondrial injury. AIDS 2017;31(9):1297\u20131301","journal-title":"AIDS"},{"issue":"9","key":"10235_CR18","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00228-014-1712-z","volume":"70","author":"A Jafari","year":"2014","unstructured":"Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol 2014;70(9):1029\u20131040","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10235_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3851\/IMP2770","volume":"19","author":"RA Bam","year":"2014","unstructured":"Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther 2014;19(7):687\u2013692","journal-title":"Antivir Ther"},{"key":"10235_CR20","doi-asserted-by":"crossref","unstructured":"Zeng QL, Yu ZJ, Ji F, Li GM, Zhang GF, Xu JH, Chen ZM, Cui GL, Li W, Zhang DW, Li J, Lv J, Li ZQ, Liang HX, Sun CY, Pan YJ, Liu YM, Wang FS. Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. Clin Infect Dis. 2021:ciaa1939","DOI":"10.1093\/cid\/ciaa1939"},{"issue":"7","key":"10235_CR21","doi-asserted-by":"publisher","first-page":"e69341","DOI":"10.1371\/journal.pone.0069341","volume":"8","author":"T Cobo","year":"2013","unstructured":"Cobo T, Kacerovsky M, Andrys C, Drahosova M, Musilova I, Hornychova H, Jacobsson B. Umbilical cord blood IL-6 as predictor of early-onset neonatal sepsis in women with preterm prelabour rupture of membranes. PLoS One. 2013;8(7):e69341","journal-title":"PLoS One"},{"key":"10235_CR22","doi-asserted-by":"crossref","unstructured":"Shim YJ, Choi BY, Park KH, Lee H, Jung YM, Kim YM. Inflammatory and Immune Proteins in Umbilical Cord Blood: Association with Hearing Screening Test Failure in Preterm Neonates. Mediators Inflamm. 2018;2018:4209359.","DOI":"10.1155\/2018\/4209359"},{"issue":"4","key":"10235_CR23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1471-0528.2007.01630.x","volume":"115","author":"AL Silberschmidt","year":"2008","unstructured":"Silberschmidt AL, K\u00fchn-Velten WN, Juon AM, Zimmermann R, von Mandach U. Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis. BJOG 2008;115(4):480\u2013485","journal-title":"BJOG"},{"issue":"3","key":"10235_CR24","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1128\/AAC.00514-10","volume":"55","author":"S Benaboud","year":"2011","unstructured":"Benaboud S, Pruvost A, Coffie PA, Ekou\u00e9vi DK, Urien S, Arriv\u00e9 E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d\u2019Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011;55(3):1315\u20131317","journal-title":"Antimicrob Agents Chemother"},{"key":"10235_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijid.2019.07.023","volume":"87","author":"X Hu","year":"2019","unstructured":"Hu X, Wang L, Xu F. Guides concerning tenofovir exposure via breastfeeding: a comparison of drug dosages by developmental stage. Int J Infect Dis 2019;87:8\u201312","journal-title":"Int J Infect Dis"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10235-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10235-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10235-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T19:46:51Z","timestamp":1634154411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10235-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10235"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10235-1","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"17 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential conflicts of interest were disclosed by Baijun Li,Zhaozhe Liu,Xing Liu,Dongchun Liu,Mingyu Duan,Ye Gu,Qiong Liu,Qiang Ma,Yushi Wei,Yan Wang.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the Ethics Committee of the Sixth People\u2019s Hospital of Shenyang (2019\u201305-002). All procedures were performed in accordance with the ethical standards of the Institutional Review Board of the Sixth People\u2019s Hospital of Shenyang, and the principles outlined in the Helsinki Declaration of 1975 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients enrolled in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}